• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Acorda’s CEO on failure, perseverance and the profound risks of drug development

Acorda’s CEO on failure, perseverance and the profound risks of drug development

July 25, 2018 By Sarah Faulkner

Acorda TherapeuticsDr. Ron Cohen isn’t easily deterred. The physician-turned-executive has spent decades in the biotech industry and weathered a number of setbacks – he learned in his early years at the now-defunct Advanced Tissue Sciences that to succeed, he needed resilience.

“I learned that it took hundreds of millions of dollars if not billions to develop a single drug successfully. I learned that the odds of success were approximately 10%. I learned that even if you were successful it probably was going to take you, on average, between 10 and 15 years,” he told Drug Delivery Business News. “And I thought that was great.”

The discouraging statistics on drug development didn’t dissuade Cohen in part because he saw it as a chance to try to bring cutting-edge science out of the laboratory and make it work for patients.

Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Biotech, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics, Massachusetts Institute of Technology

More recent news

  • Former Shockwave Medical CEO joins Solenic Medical’s board
  • Anaconda Biomed brings in $56 million
  • Precision Neuroscience raises $250M in Series D for its BCI
  • Fresenius discontinuing Chinese sales of 4008A hemodialysis system
  • Perfuze’s super-bore stroke catheter tops conventional, cyclic aspiration in bench study

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy